Regulation guidance on fair and reasonable pricing: Provided further , That the Secretary may take such measures authorized under current law to ensure that vaccines, therapeutics, and diagnostics developed from funds provided in this Act will be affordable in the commercial market: Provided further , That in carrying out the previous proviso, the Secretary shall not take actions that delay the development of such products: Provided further , That the Secretary shall ensure that protections remain for individuals enrolled in group or individual health care coverage with pre-existing conditions, including those linked to coronavirus: Provided further , That products purchased with funds appropriated under this paragraph in this Act may, at the discretion of the Secretary of Health and Human Services, be deposited in the Strategic National Stockpile under section 319F–2 of the Public Health Service Act ( 42 U.S.C. 247d–6b ): Provided further , That of the amount appropriated under this paragraph in this Act, not more than $2,000,000,000 shall be for the Strategic National Stockpile under section 319F–2(a) of such Act: Provided further , That funds appropriated under this paragraph in this Act may be transferred to, and merged with, the fund authorized by the Covered Counter Measure Process Fund under section 319F–4 of the Public Health Service Act ( 42 U.S.C. 247d–6e ): Provided further , That of the amount appropriated under this paragraph in this Act, $20,000,000,000 shall be available to the Biomedical Advanced Research and Development Authority for necessary expenses of manufacturing, production, and purchase, at the discretion of the Secretary, of vaccines, therapeutics, diagnostics, and small molecule active pharmaceutical ingredients, including the development, translation, and demonstration at scale of innovations in manufacturing platforms: Provided further , That funds in the previous proviso may be used for the construction or renovation of United States-based next generation manufacturing facilities,